NetworkNewsBreaks

TuesdayApr 04, 2023 11:52 am

NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Inks LOI for Acquisition of Ketamine Wellness Centers

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has signed a letter of intent with Peter/PetraMD, the largest online provider of hormone therapy in the United States for the acquisition of Ketamine Wellness Centers. According to the announcement, the acquisition provides an incredible on-ramp into the ketamine space for Peter/PetraMD, which has more than 20 years of experience and nearly 100,000 patients across the United States. Ketamine Wellness Centers is the largest ketamine infusion therapy provider in the country. According to the announcement, Peter/PetraMD plans to maintain continuity of care…

Continue Reading

MondayApr 03, 2023 3:19 pm

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is positioned for opportunity with its patented DehydraTECH(TM) technology and its wide-reaching potential. “Lexaria’s DehydraTECH is designed to formulate and deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (‘APIs’). DehydraTECH increases the effectiveness of and improves the way APIs enter the bloodstream. The benefits of consuming a DehydraTECH-enabled drug or product include: speed up in delivery time; increased bioavailability; increased brain absorption; improved drug potency; and reduction in drug administration costs. Animal studies of DehydraTECH have demonstrated the ability to elevate the quantity of the drug delivered across…

Continue Reading

MondayApr 03, 2023 2:56 pm

NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies

BiondVax (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits clear competitive advantages over existing monoclonal antibodies (“mAbs”) and oral therapies. “According to statistically significant results released early January, BiondVax established that its inhaled therapy virtually eliminated the SARS-CoV-2 virus and prevented illness when administered prophylactically… The second set of results, announced January 23, evidenced that when the NanoAb was administered by inhalation three hours before infection,…

Continue Reading

MondayApr 03, 2023 2:46 pm

NetworkNewsBreaks – Endeavor Group Holdings Inc. (NYSE: EDR) Moves in Rare Opportunity to Form Global Live Sports and Entertainment Pureplay

Endeavor (NYSE: EDR), the parent company of UFC, was featured in a recent Fox Business article that discussed the company’s deal to acquire World Wrestling Entertainment Inc. (NYSE: WWE) from Vince McMahon and form a new public company. “Endeavor will hold a 51% controlling interest in the new company while WWE shareholders will have a 49% stake. The deal values UFC at $12.1 billion and WWE at $9.3 billion. The announcement comes hours after WWE hosted WrestleMania 39 in Inglewood, California,” the article reads. “This is a rare opportunity to create a global live sports and entertainment pureplay built for…

Continue Reading

MondayApr 03, 2023 2:34 pm

NetworkNewsBreaks – McEwen Mining Inc.’s (NYSE: MUX) (TSX: MUX) Subsidiary Collaborating in Vision to ‘Build a Mine for the Future’

McEwen Mining’s (NYSE: MUX) (TSX: MUX) 51.9%-owned subsidiary, McEwen Copper, recently closed an ARS 30 billion investment by FCA Argentina S.A., a subsidiary of Stellantis N.V. (NYSE: STLA). Proceeds from the investment are expected to be directed toward advancing the development of McEwen Copper’s 100%-owned Los Azules project in San Juan, Argentina. “We are delighted to have Stellantis as a partner in the future development of our Los Azules copper project,” McEwen Copper CEO Rob McEwen is quoted as saying of the investment. “Together, we share a vision to build a mine for the future based on regenerative principles that…

Continue Reading

MondayApr 03, 2023 2:23 pm

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Announces New PO from California College, New Service Deal with Denver Airport

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, has received an order from Mt. San Antonio College. The order is for 11 K1 Blue Light Towers and 7 K1 Emergency Phones along with a one-year full-service maintenance plan. In addition, the company inked a deal with the Denver International Airport Annual to provide a monitoring and wireless service plan for 40 K1 Call Boxes that are installed along the main road leading to and from the airport as well as at other locations around the airport property. Located in California, Mt. San…

Continue Reading

MondayApr 03, 2023 1:30 pm

NetworkNewsBreaks – YanGuFang International Group Co. Ltd. (NASDAQ: YGF) Closes Initial Public Offering

YanGuFang International Group (NASDAQ: YGF), a healthy food company primarily engaged in the production, research and development, and sales of oat and grain products, recently announced the closing of its initial public offering of 2,000,000 ordinary shares, each at a public offering price of US$4.00. The ordinary shares began trading on the Nasdaq Capital Market under the ticker symbol YGF on March 28, 2023. YanGuFang International Group received aggregate gross proceeds of US$8.0 million from the offering, before deducting underwriting discounts and other related expenses. The company has additionally granted the underwriters a 45-day option to purchase up to an…

Continue Reading

MondayApr 03, 2023 1:07 pm

NetworkNewsBreaks – Hongli Group Inc. (NASDAQ: HLP) Secures US$8.25M in Initial Public Offering

Hongli Group (NASDAQ: HLP) has closed its initial public offering of 2,062,500 ordinary shares, each at a public offering price of $4.00, for total gross proceeds of $8.25 million before deducting underwriting discounts and offering expenses. The offering was conducted on a firm commitment basis. In addition, Hongli Group granted the underwriters an option, exercisable within 45 days from the effective date of the company’s registration statement on Form F-1 (File No. 333-261945), as amended, in connection with the offering, to purchase up to an additional 309,375 ordinary shares at the public offering price, less underwriting discounts and commissions, to…

Continue Reading

MondayApr 03, 2023 12:59 pm

NetworkNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Q4 and FY 2022 Financial Results

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced results for the fourth quarter and year ended Dec. 31, 2022. Among the highlights, the company reported $6,196,743 in revenues compared to $2,876,273 for the year ended Dec. 31, 2021. “I am extremely pleased with how far we have come in such a short time,” said Brian John, CEO of Jupiter Wellness. “In 2022, we shifted out of the CBD space and acquired and established new unique IP and products with little competition. We look forward to focusing on selling our brands and becoming profitable…

Continue Reading

MondayApr 03, 2023 12:42 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces FY 2022 Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the full year ended Dec. 31, 2022. The company also provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of 2022, we made significant advancements in our ongoing clinical trial for Berubicin. We have expanded our clinical trial sites across Europe and continued with an encouraging and increasingly rapid pace of…

Continue Reading